Description
Smoking cessation is among the most dynamic markets within the pharma, biotech and healthcare sector, and expected to grow despite the current economic times. According to Smoking Cessation 2009-2024 report , the evolution of NRTs - including neuroreceptor modulators, enzyme inhibitors and therapeutic vaccines - will push worldwide sales of smoking cessation drugs to $1.5 billion by 2010, with majority of revenues coming from the NRTs.
Recently, the current marketed drugs have come under strict FDA regulations highlighting low safety and efficacy of existing smoking cessation products. These restraints will further strengthen the scope for robust drug pipeline and newer opportunities that will revolutionise the global smoking cessation landscape.
Following the success of our series of conferences in the UK and US, the 4th Annual Smoking Cessation conference, will discuss current challenges, unmet medical needs, scope and future treatments in the smoking cessation market. With an impressive line-up of speakers and topical themes, you will gain an international perspective on the future tobacco control activities and treatments to reduce the impact of smoking globally.
